Lymphoma, Primary Effusion
Oncology·MeSH: Lymphoma, Primary Effusion
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Daratumumab SC | FATE THERAPEUTICS INC (FATE) |
Frequently asked questions
How many drugs are in development for Lymphoma, Primary Effusion?
BioSniper tracks 1 drug in development for Lymphoma, Primary Effusion across 1 company.
How many clinical trials target Lymphoma, Primary Effusion?
There are 1 clinical trial targeting Lymphoma, Primary Effusion tracked by BioSniper.
What is the prevalence of Lymphoma, Primary Effusion?
The estimated prevalence of Lymphoma, Primary Effusion is approximately 56.0 per 100,000 population.
Deep-dive into Lymphoma, Primary Effusion
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis